Non-alcoholic Steatohepatitis Treatment Market Share,Size and Forecast

SKU: DHC255 | Last Updated On: Jul 31 2019 | No. of Pages: 231 | Available Formats

In June 2019, GENFIT announced the launch of a P2 clinical trial to evaluate the effect of elafibranor in patients with Nonalcoholic Fatty Liver.

NASH (Non-alcoholic Steatohepatitis) Treatment Market

NASH (Non-alcoholic Steatohepatitis) Treatment Market

The Global NASH (Non-alcoholic Steatohepatitis) Treatment market was valued at USD XX million in 2018 and expected to grow at a CAGR of XX% to reach a market value of USD XX million by 2026.

Nonalcoholic steatohepatitis (NASH) is a progressive form of nonalcoholic fatty liver disease (NAFLD) in which there is an abnormal accumulation of fat in the liver. This can lead to inflammation and liver cell damage, which can cause liver fibrosis or scarring and may further progress to cirrhosis or liver cancer. NASH is known to be chronic yet silent disease with few or no symptoms and is often unrecognized and underdiagnosed. Risk factors of NASH include diabetes, obesity, insulin resistance, abnormal levels of cholesterol, and metabolic syndrome.

Graph

Global NASH (Non-alcoholic Steatohepatitis) Treatment Market  Dynamics

The global market for the NASH (non-alcoholic steatohepatitis) treatment market is primarily driven by the rising prevalence of NASH and the strong presence of pipeline drug. For instance, Pfizer is currently researching multiple ways to treat NASH at its different stages of progression. The company entered into a non-exclusive clinical development agreement with Novartis to investigate one or more combination therapies for the treatment of NASH. Owing to lack of symptoms, NASH is often unrecognized and underdiagnosed, but it is believed to affect over 6% of the adult population worldwide, and with no currently available treatments, NASH is most likely to be the leading cause for liver transplant by 2020. Other factors such as the growing prevalence of diabetes, obesity, and rising demand for therapeutics are expected to influence the market growth further. As there are no therapeutic options approved to treat patients with NASH currently, there is a high unmet need for the drugs, and as a result, any new drug launched is expected to see rapid acceptance buy patients with NASH. According to the International Diabetes Federation, Diabetes Atlas Eighth edition 2017, about 425 million adults are diabetic worldwide, and by 2045, the diabetic population is estimated to rise to 629 million. According to WHO, in 2016, over 1.9 billion adults (18+ population) were overweight, of which over 650 million adults were obese. Overall, around 13% of the world’s adult population (11% of men and 15% of women) were obese in 2016.

However, the lack of demand in developing countries and insufficient diagnostic technologies for NASH may hinder market progress. 

Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – Segment Analysis

By Drug, the global NASH (Non-alcoholic Steatohepatitis) Treatment market is segmented into Vitamin E, Pioglitazone, Ocaliva, Elafibranor, and Selonsertib & Cenicriviroc and others. Vitamin E and Pioglitazone segments currently hold the most significant market shares due to their efficacy. Some studies suggest that pioglitazone, a treatment for type 2 diabetes, improves NASH in patients that don’t have diabetes. Another study by the National Institute of Diabetes and Digestive and Kidney Diseases’ NASH Clinical Research Network identified that treatment with vitamin E or pioglitazone improved NASH in about half of the people treated. However, there is no clinical validation for the long term effects of this treatment. On the other hand, elafibranor and selonsertib & cenicriviroc shares are anticipated to show significant growth due to many drugs currently in the pipeline.

Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – Geographical Analysis

North America occupied a dominant market share of the global NASH treatment market in 2018. Market dominance is mainly attributed to factors such as the rising prevalence of obesity & diabetes, increasing incidence of NASH, and robust pipeline drugs among local players. For instance, in June 2019, Crown Bioscience announced four new preclinical translational NASH models are in development. According to NIH, approximately 12% of US adults suffer from NASH, which is approximately 30 million people, and the prevalence is projected to increase by over 60% between 2015 and 2030. According to the National Diabetes Statistics Report, in 2017, 30.3 million people in the US have diabetes, which is nearly one in 10 Americans. According to the CDC, in 2016, the obesity prevalence rate  was 39.8%, and the condition affected approximately 93.3 million adults in the US. Moreover, the advanced regional healthcare infrastructure, rise in healthcare expenditure, presence of established market players and high investment in R&D activities by them are likely to boost the North America NASH Treatment market growth.

Pie Chat

Global NASH (Non-alcoholic Steatohepatitis) Treatment Market– Competitive Analysis

To increase the user base and improve their NASH (Non-alcoholic Steatohepatitis) Treatment market presence, companies are increasingly investing in R&D to have a strong drug pipeline. Moreover, several key companies have adopted merger and acquisitions policies, clinical agreements, and collaborations to improve market presence also expand its geographical footprint in the global NASH treatment market.

Major Players in the global NASH Treatment market include Allergan plc, Pfizer Inc., and Novartis AG.

In June 2019, Crown Bioscience announced four new preclinical translational NASH models in development.

In June 2019, GENFIT, initiated a Phase II clinical trial to evaluate the effect of a 6-week, once daily treatment of elafibranor (120mg) vs. placebo on hepatic lipid composition in patients with Nonalcoholic Fatty Liver (NAFL).

In April 2019, Novartis announced the acquisition of IFM Tre, a subsidiary of IFM Therapeutics LLC. The acquisition is anticipated to provide Novartis full rights to IFM Tre's portfolio of NLRP3 inhibitors which includes – IFM-2427, a clinical-stage systemic antagonist for an array of chronic inflammatory disorders, such as gout, atherosclerosis and NASH.

In October 2018, Pfizer Inc. and Novartis signed a non-exclusive clinical development agreement for clinical investigation of one or more combination therapies for the treatment of NASH. The companies together will conduct both non-clinical and Phase 1 clinical studies of Pfizer’s investigational drug therapies, including acetyl CoA-carboxylase inhibitor (PF-05221304, currently in Phase II), a diacylglycerol O-Acyltransferase 2 (DGAT2) inhibitor (PF-06865571, Phase 1) and a ketohexokinase (KHK) inhibitor (PF-06835919, Phase 2), along with Novartis’s tropifexor, a non-bile acid, farnesoid X receptor (FXR) agonist.

In April 2017, Allergan entered into a clinical trial agreement with Novartis to conduct a Phase IIb study, using Allergan's cenicriviroc (CVC) and Novartis' lead FXR agonist for the treatment of NASH. The Phase IIb study will evaluate safety, efficacy, and tolerability of this multi-therapy treatment approach for NASH. 

Key Takeaways:

·       The global market for the NASH (Non-alcoholic Steatohepatitis) Treatment Market is primarily driven by the rising prevalence of NASH and the strong presence of pipeline drug. Other factors such as the growing prevalence of diabetes, obesity, and rising demand for therapeutics are expected to influence the market growth further.

·       Vitamin E and Pioglitazone segments currently hold the most significant market shares due to their efficacy.

·       North America accounts for the largest share in the global NASH Treatment market, owing to factors such as the rising prevalence of obesity and diabetes, increasing incidence of NASH, and recent drug approvals.

·       Adopting merger and acquisitions policies, clinical collaborations, and regional expansion to help key market players to stand out as strong competitors in the NASH treatment market.

Why Purchase the Report?

·       Visualize the composition of the global NASH (Non-alcoholic Steatohepatitis) Treatment Market across each indication, in terms of Type and Application options, highlighting the key commercial assets and players.

·       Identify commercial opportunities in global NASH (Non-alcoholic Steatohepatitis) Treatment Market by analyzing trends and co-development deals.

·       Excel data sheet with thousands of data points of the global NASH (Non-alcoholic Steatohepatitis) Treatment Market - level 4/5 segmentation.

·       PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

·       Type mapping in excel for the key Services of all major market players

Target Audience:

·       Equipment Suppliers/ Buyers

·       Type Providers/ Buyers

·       Industry Investors/Investment Bankers

·       Education & Research Institutes

·       Research Professionals

·       Emerging Companies

·       Manufacturers

Global NASH (Non-alcoholic Steatohepatitis) Treatment Market

1. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market -Scope and Methodology

1.1. Research Methodology

1.2. Scope of the market

2. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market -Key Trends and Developments

2.1. Key Trends and Developments

3. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – Executive Summary

3.1. Market Snippet By Distribution Channels

3.2. Market Snippet By Drug

3.3. Market Snippet By Region

3.4. DataM CLO Scenario

4. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market Dynamics

4.1. Market impacting factors

4.2. Drivers

4.2.1. Rise in NASH-affected population

4.2.2. Increasing prevalence of diabetes & obesity

4.2.3. Driver 3

4.3. Restraints

4.3.1. Insufficient diagnostic technologies for NASH

4.3.2. Restraint 3

4.4. Opportunity

4.5. Impact analysis

5. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – Industry Analysis

5.1. Porter's five forces analysis

5.2. Supply chain analysis

5.3. Pricing analysis

5.4. Regulatory analysis

5.5. Pipeline analysis

6. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – By Drug

6.1. Introduction

6.2. Market size analysis, and y-o-y growth analysis (%), By Drug segment

6.3. Market attractiveness index, By Drug segment

6.4. Vitamin E

6.4.1. Introduction

6.4.2. Market size analysis, y-o-y growth analysis (%)

6.5. Pioglitazone

6.6. Ocaliva

6.7. Elafibranor

6.8. Selonsertib & Cenicriviroc

6.9. Others

7. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – By Distribution Channels

7.1. Introduction

7.2. Market size analysis, and y-o-y growth analysis (%), By Distribution Channels segment

7.3. Market attractiveness index, By Distribution Channels segment

7.4. Hospital pharmacy

7.4.1. Introduction

7.4.2. Market size analysis, and y-o-y growth analysis (%)

7.5. Retail pharmacy

7.6. Online providers

8. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – By Region

8.1. Introduction

8.2. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region

8.3. Market Attractiveness Index, By Region

8.4. North America

8.4.1. Introduction

8.4.2. Key region-specific dynamics

8.4.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.4.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.4.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.4.5.1.         U.S.

8.4.5.2.         Canada

8.4.5.3.         Mexico

8.5. Europe

8.5.1. Introduction

8.5.2. Key Region-Specific Dynamics

8.5.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.5.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.5.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.5.5.1.         Germany

8.5.5.2.         U.K.

8.5.5.3.         France

8.5.5.4.         Italy

8.5.5.5.         Spain

8.5.5.6.         Rest of Europe

8.6. South America

8.6.1. Introduction

8.6.2. Key Region-Specific Dynamics

8.6.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.6.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.6.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.6.5.1.         Brazil

8.6.5.2.         Argentina

8.6.5.3.         Rest of South America

8.7. Asia Pacific

8.7.1. Introduction

8.7.2. Key Region-Specific Dynamics

8.7.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.7.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

8.7.5. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Countries

8.7.5.1.          China

8.7.5.2.         India

8.7.5.3.         Japan

8.7.5.4.         Australia

8.7.5.5.         Rest of Asia Pacific

8.8. The Middle East And Africa

8.8.1. Introduction

8.8.2. Key Region-Specific Dynamics

8.8.3. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Drug

8.8.4. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Distribution Channels

9. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – Competitive Landscape

9.1. Competitive scenario

9.2. Competitor strategy analysis

9.3. Comparative type portfolio analysis

9.4. Market positioning/share analysis

9.5. Mergers and acquisitions analysis

10. Company Profiles

10.1. Allergan plc.

10.1.1. Company Overview

10.1.2. Type Portfolio And Description

10.1.3. Key Highlights

10.1.4. Financial Overview

10.2. Pfizer Inc

10.3. Gilead Sciences, Inc.

10.4. Genfit SA

10.5. Novartis AG

10.6. Intercepts Pharmaceuticals

10.7. Cadila Healthcare Ltd

10.8. Novo Nordisk

10.9. Raptor Pharmaceutical Corp.

10.10. Galmed Pharmaceuticals Ltd.

11. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – Premium Insights

12. Global NASH (Non-alcoholic Steatohepatitis) Treatment Market – DataM

12.1. Appendix

12.2. About us and services

12.3. Contact Us

LIST OF TABLES

1.      Global Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2018,2022 & 2026 ($ Million)

2.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2018,2022 & 2026 ($ Million)

3.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Region, 2018,2022 & 2026 ($ Million)

4.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2018,2022 & 2026 ($ Million)

5.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2017-2026 ($ Million)

6.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2018,2022 & 2026 ($ Million)

7.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2017-2026 ($ Million)

8.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Region, 2018,2022 & 2026 ($ Million)

9.     Global Non-alcoholic Steatohepatitis Treatment Market Value, By Region, 2017-2026 ($ Million)

10.  North America Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2017-2026 ($ Million)

11.   North America Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2017-2026 ($ Million)

12.  North America Non-alcoholic Steatohepatitis Treatment Market Value, By Country, 2017-2026 ($ Million)

13.  South America Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2017-2026 ($ Million)

14.  South America Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2017-2026 ($ Million)

15.  South America Non-alcoholic Steatohepatitis Treatment Market Value, By Country, 2017-2026 ($ Million)

16.  Europe Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2017-2026 ($ Million)

17.  Europe Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2017-2026 ($ Million)

18.  Europe Non-alcoholic Steatohepatitis Treatment Market Value, By Country, 2017-2026 ($ Million)

19.  Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2017-2026 ($ Million)

20. Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2017-2026 ($ Million)

21.  Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Value, By Country, 2017-2026 ($ Million)

22. Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Value, By Drug Type, 2017-2026 ($ Million)

23. Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Value, By Distribution Channels, 2017-2026 ($ Million)

24. Allergan plc : Overview

25. Allergan plc : Product Portfolio

26. Allergan plc : Key Developments

27.  Pfizer Inc: Overview

28. Pfizer Inc: Product Portfolio

29. Pfizer Inc: Key Developments

30. Gilead Sciences, Inc.: Overview

31.  Gilead Sciences, Inc.: Product Portfolio

32. Gilead Sciences, Inc.: Key Developments

33. Genfit SA: Overview

34. Genfit SA: Product Portfolio

35. Genfit SA: Key Developments

36. Novartis AG: Overview

37.  Novartis AG: Product Portfolio

38. Novartis AG: Key Developments

39. Intercepts Pharmaceuticals: Overview

40. Intercepts Pharmaceuticals: Product Portfolio

41.  Intercepts Pharmaceuticals: Key Developments

42. Cadila Healthcare Ltd: Overview

43. Cadila Healthcare Ltd: Product Portfolio

44. Cadila Healthcare Ltd: Key Developments

45. Novo Nordisk: Overview

46. Novo Nordisk: Product Portfolio

47.  Novo Nordisk: Key Developments

48. Raptor Pharmaceutical Corp.: Overview

49. Raptor Pharmaceutical Corp.: Product Portfolio

50. Raptor Pharmaceutical Corp.: Key Developments

51.  Galmed Pharmaceuticals Ltd: Overview

52. Galmed Pharmaceuticals Ltd: Product Portfolio

53. Galmed Pharmaceuticals Ltd: Key Developments

LIST OF FIGURES

1.      Global Non-alcoholic Steatohepatitis Treatment Market Share, By Drug Type, 2018 & 2026 (%)

2.     Global Non-alcoholic Steatohepatitis Treatment Market Share, By Distribution Channels, 2018 & 2026 (%)

3.     Global Non-alcoholic Steatohepatitis Treatment Market Share, By Region, 2018 & 2026 (%)

4.     Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

5.     Global Non-alcoholic Steatohepatitis Treatment Market Y-o-Y Growth, By Drug Type, 2018-2026 (%)

6.     Vitamin E: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

7.     Pioglitazone: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

8.     Obeticholic acid: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

9.     Elafibranor: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

10.  Simtuzumab and Liraglutide: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

11.   Others: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

12.  Global Non-alcoholic Steatohepatitis Treatment Market Y-o-Y Growth, By Distribution Channels, 2018-2026 (%)

13.  Hospital pharmacy: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

14.  Retail pharmacy: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

15.  Online providers: Global Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

16.  Global Non-alcoholic Steatohepatitis Treatment Market Y-o-Y Growth, By Region, 2018-2026 (%)

17.  North America Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

18.  North America Non-alcoholic Steatohepatitis Treatment Market Share, By Drug Type, 2018 & 2026 (%)

19.  North America Non-alcoholic Steatohepatitis Treatment Market Share, By Distribution Channels, 2018 & 2026 (%)

20. North America Non-alcoholic Steatohepatitis Treatment Market Share, By Country, 2018 & 2026 (%)

21.  South America Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

22. South America Non-alcoholic Steatohepatitis Treatment Market Share, By Drug Type, 2018 & 2026 (%)

23. South America Non-alcoholic Steatohepatitis Treatment Market Share, By Distribution Channels, 2018 & 2026 (%)

24. South America Non-alcoholic Steatohepatitis Treatment Market Share, By Country, 2018 & 2026 (%)

25. Europe Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

26. Europe Non-alcoholic Steatohepatitis Treatment Market Share, By Drug Type, 2018 & 2026 (%)

27.  Europe Non-alcoholic Steatohepatitis Treatment Market Share, By Distribution Channels, 2018 & 2026 (%)

28. Europe Non-alcoholic Steatohepatitis Treatment Market Share, By Country, 2018 & 2026 (%)

29. Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

30. Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Share, By Drug Type, 2018 & 2026 (%)

31.  Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Share, By Distribution Channels, 2018 & 2026 (%)

32. Asia-Pacific Non-alcoholic Steatohepatitis Treatment Market Share, By Country, 2018 & 2026 (%)

33. Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Value, 2017-2026 ($ Million)

34. Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Share, By Drug Type, 2018 & 2026 (%)

35. Middle East & Africa Non-alcoholic Steatohepatitis Treatment Market Share, By Distribution Channels, 2018 & 2026 (%)

36. Allergan plc : Financials

37.  Pfizer Inc: Financials

38. Gilead Sciences, Inc.: Financials

39. Genfit SA: Financials

40. Novartis AG: Financials

41.  Intercepts Pharmaceuticals: Financials

42. Cadila Healthcare Ltd: Financials

43. Novo Nordisk: Financials

44. Raptor Pharmaceutical Corp.: Financials

45. Galmed Pharmaceuticals Ltd: Financials

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report



Get your FREE SAMPLE PROPOSAL with a single click!